Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: Long-term results from a single institution

Haematologica

Volumn 98, Issue 7, 2013, Pages 1142-1146

  Tovar, Natalia ^a   de Larrea, Carlos Fernández ^a   Aróstegui, Juan I ^a   Cibeira, Maria Teresa ^a   Rosiñol, Laura ^a   Rovira, Montserrat ^a   Elena, Montserrat ^a   Filella, Xavier ^a   Yagüe, Jordi ^a   Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN KAPPA CHAIN; OLIGOCLONAL BAND; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; LIGHT CHAIN; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMACYTOMA; PREVALENCE; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SEROLOGY; SYSTEMATIC REVIEW;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, HUMORAL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOCLONAL BANDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84879560303     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084350     Document Type: Article

References (26)

1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
2. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18): 4701-5.
3. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol.1998;102(5): 1115-23.
4. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-73.
5. Fernández de Larrea C, Cibeira MT, Elena M, Arostegui JI, Rosiñol L, Rovira M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood. 2009;114(24):4954-6.
6. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998;91(9):3518-23.
7. Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smith Sibinga CT, et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant. 2000;25(7):723-8.
8. Hall SL, Tate J, Gill D, Mollee P. Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin Biochem Rev. 2009;30(3):113-8.
9. Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008;143 (5):654-60.
10. Fernández de Larrea C, Tovar N, Cibeira MT, Arostegui JI, Rosiñol L, Elena M, et al. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica. 2011;96(1):171-3.
11. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115(18):3655-63.
12. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 2011;118(11):2985-7.
13. Manson GV, Campagnaro E, Balog A, Kaplan D, Sommers SR, Fu P, et al. Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance. Bone Marrow Transplant. 2012;47(9):1212-6.
14. Byrne E, Giles C, Andrews J, Rahemtulla A, Naresh KN. Lack of correlation between emergence of an abnormal protein band or of oligoclonal bands and survival in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation. Haematologica. 2011;96 (4):e29.
15. Mitus AJ, Stein R, Rappeport JM, Antin JH, Weinstein J, Alper CA, Smith BR. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood. 1989;74:2764-8.
16. Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: A recapitulation of normal B-cell ontogeny. Blood. 1990;76(8):1647-56.
17. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613-23.
18. Brito-Zerón P, Retamozo S, Gandía M, Akasbi M, Pérez-de-Lis M, Diaz-Lagares C, et al. Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun. 2012;39(1-2):43-8.
19. Gerritsen EJ, Van Tol MJ, Lankester AC, van der Weijden-Ragas CP, Jol-van der Zijde CM, Oudeman-Gruber NJ, et al. Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation. Blood. 1993;82(11): 3493-502.
20. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-20.
21. Guikema JE, Vellenga E, Veeneman JM, Hovenga S, Bakkus MH, Klip H, Bos NA. Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. Br J Haematol. 104(4):748-54.
22. Byrne E, Naresh KN, Giles C, Rahemtulia A. Excess bone marrow B-cells in patients with multiple myeloma achieving complete remission after autologous stem cell transplant is a biomarker for improved survival. Br J Haematol. 2011;155(4):509-11.
23. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-12.
24. Pratt G, Mead GP, Godfrey KR, Hu Y, Evans MD, Chappell MJ, et al. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma. 2006;47(1):21-8.
25. Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M. Antigen specificity of oligoclonal abnormal protein bands in multiple myeloma after allogenic stem cell transplantation. Cancer Immunol Immunother. 2012,61(10):1639-51.
26. Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009; 114(15):3276-84.